Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.2K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.2K
Overview of Hematopoiesis01:20

Overview of Hematopoiesis

4.0K
Hematopoiesis, or blood cell production, is a vital biological process that begins early in embryonic development and continues throughout life. This process generates the various types of cells found in blood, including red blood cells, white blood cells, and platelets from hematopoietic stem cells (HSCs).
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...
4.0K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.9K
Lineage Commitment01:21

Lineage Commitment

3.0K
Commitment is the  process whereby stem cells:
3.0K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

331
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
331
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

3.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hijacking the bone niche: mechanistic insights into bone metastasis in breast cancer.

Bone research·2026
Same author

Erratum to: Ononin inhibits triple-negative breast cancer lung metastasis by targeting the EGFR-mediated PI3K/Akt/mTOR pathway.

Science China. Life sciences·2026
Same author

Isoliquiritigenin Inhibits Triple-Negative Breast Cancer Progression via Targeting the IRF5/SLC7A5/IDO1-Mediated Tryptophan Metabolism Pathway.

Oncology research·2025
Same author

PRMT1-Mediated PARP1 Methylation Drives Lung Metastasis and Chemoresistance via P65 Activation in Triple-Negative Breast Cancer.

Research (Washington, D.C.)·2025
Same author

CircPLK1 upregulates ETS1 to confer anthracycline resistance in triple-negative breast cancer.

Journal of translational internal medicine·2025
Same author

Isoliquiritigenin reduces brain metastasis by circNAV3-ST6GALNAC5-EGFR axis in triple-negative breast cancer.

Cancer letters·2025

Related Experiment Video

Updated: Jul 4, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:39

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

100

JAK/STAT in leukemia: a clinical update.

Dong Liang1, Qiaoli Wang1, Wenbiao Zhang1

  • 1State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, China.

Molecular Cancer
|January 25, 2024
PubMed
Summary
This summary is machine-generated.

This review details the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway's role in leukemia development. It highlights advancements in JAK/STAT inhibitors for leukemia therapy and ongoing clinical trials.

Keywords:
JAK/STAT inhibitorsJAK/STAT signaling pathwayLeukemia

More Related Videos

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.3K
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.0K

Related Experiment Videos

Last Updated: Jul 4, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:39

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

100
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.3K
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.0K

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • The Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway is crucial in cellular processes.
  • Dysregulation of the JAK/STAT pathway, particularly the JAK2V617F mutation, is implicated in myeloproliferative neoplasms (MPNs) and leukemia.
  • Decades of research have focused on understanding this pathway's role in leukemogenesis.

Purpose of the Study:

  • To review recent advancements in understanding the JAK/STAT signaling pathway's involvement in leukemia.
  • To summarize the current therapeutic applications of JAK/STAT inhibitors in leukemia treatment.
  • To explore ongoing clinical trials investigating JAK/STAT inhibitors for leukemia.

Main Methods:

  • Literature review of scientific publications and clinical trial databases.
  • Synthesis of research findings on JAK/STAT pathway activation in leukemia.
  • Analysis of data from clinical trials involving JAK/STAT inhibitors.

Main Results:

  • The JAK/STAT pathway is a significant driver in the development and progression of various leukemia types.
  • JAK/STAT inhibitors have demonstrated efficacy in treating certain leukemias, particularly those with specific mutations.
  • Several clinical trials are evaluating the safety and effectiveness of novel JAK/STAT inhibitors in leukemia patients.

Conclusions:

  • The JAK/STAT pathway is a critical target for leukemia therapy.
  • Targeted inhibition of the JAK/STAT pathway offers a promising therapeutic strategy for leukemia.
  • Continued research and clinical trials are essential to optimize JAK/STAT inhibitor-based treatments for leukemia.